Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO),
today announced that the company’s 2024 Annual Meeting of
Shareholders (“Annual Meeting”) was convened and adjourned, without
any business being conducted, due to lack of the required quorum.
Message from Ilan Danieli, CEO:
During this process, we’ve realized that there
are quite a few shareholders who didn’t know whether their shares
were voted on or not.
If you are not sure if your shares were voted,
you should be able to see that information on your broker portal
when you log in. If you can’t find that information, please reach
out to your broker and ask them – it’s an easy and quick phone
call and they will let you know right away.
If your shares were not voted – PLEASE,
MAKE SURE THEY GET VOTED.
You can accomplish this in one of three easy
ways that will take no more than 60 seconds:
- Ask the broker to vote for your
shares.
- Request your 16-digit control
number, and you can vote for the shares yourself by going to
www.proxyvote.com.
- Log into your brokerage account and
there should be a button to vote the shares.
Regardless of whether you vote for or against
the measures presented, what’s important is to vote. As a
shareholder, it is in YOUR BEST INTEREST that the company reaches a
quorum so that it avoids costly procedures to complete the annual
shareholder meeting.
A quorum consists of the presence at the Annual
Meeting either online during the live audio webcast or represented
by proxy of the holders of a majority of the voting power of our
outstanding shares of common stock entitled to vote at the Annual
Meeting. There were fewer than a majority of shares entitled to
vote present, either in person or by proxy at the Annual Meeting.
The Annual Meeting, therefore, had no quorum, and accordingly, the
Annual Meeting has been adjourned. The Annual Meeting will resume
with respect to all proposals at 9 a.m. Eastern Time on Friday,
June 21, 2024, and will continue to be held virtually.
The record date for determining shareholders
eligible to vote at the Annual Meeting will remain the close of
business on April 19, 2024. Shareholders who have already submitted
a proxy do not need to vote again for the reconvened Annual
Meeting, as the proxies submitted will remain valid. Shareholders
who have already submitted proxies and would like to change their
vote with respect to any of the proposals can update their vote in
the manner set forth in the Definitive Proxy Statement. Your vote
will be recorded at the Annual Meeting in accordance with your most
recently submitted proxy.
Precipio’s shareholders as of close of business
on the April 19, 2024 record date who have not yet voted are
encouraged to vote online at www.proxyvote.com or by telephone
at 1-800-690-6903.
Voting on all proposals will be open until the
conclusion of Precipio’s 2024 Annual Meeting on Friday, June 21,
2024. Votes Submitted through the Internet or your broker must be
submitted by 11:59 p.m., Eastern Time, on June 20,
2024.
Please note: if your shares are held in a
brokerage account or by a bank or other holder of record, you are
considered the “beneficial owner” of shares held in “street name.”
The proxy materials have been forwarded to you by your broker, bank
or other nominee who is considered, with respect to those shares,
the stockholder of record. As the beneficial owner, you have the
right to direct your broker, bank or other holder of record on how
to vote your shares by following their instructions for voting.
Please refer to information from your bank, broker or other nominee
on how to submit your voting instructions.
You may also vote at www.proxyvote.com. You will
need the 16-digit control number included on the Notice of Internet
Availability of Proxy Materials or the proxy card.
A copy of the Definitive Proxy Statement is
available to shareholders on the Company’s website and at the
website maintained by the SEC at www.sec.gov.
Precipio shareholders as of the April 19, 2024
record date for the Annual Meeting are invited to attend the
virtual Annual Meeting by visiting
www.virtualshareholdermeeting.com/PRPO2024.
Additional Information and where to find
it
This material may be deemed to be solicitation
material in respect of the Annual Meeting to be reconvened and held
on June 19, 2024. On April 29, 2024. The Company has filed a
Definitive Proxy Statement and associated proxy card with the U.S.
Securities and Exchange Commission (the “SEC”) in connection with
the solicitation of proxies for the Annual Meeting. The Company,
its directors, its executive officers and certain other individuals
set forth in the Definitive Proxy Statement will be deemed
participants in the solicitation of proxies from stockholders in
respect of the Annual Meeting. Information regarding the names of
the company’s directors and executive officers and certain other
individuals and their respective interests in the Company has been
included in the definitive proxy statement filed with the SEC on
April 29, 2024. Details containing the nominees of the Company’s
Board of Directors for election at the 2024 Annual Meeting of
Stockholders are included in the definitive proxy statement. BEFORE
MAKING ANY VOTING DECISION, STOCKHOLDERS OF THE COMPANY ARE URGED
TO READ ALL RELEVANT DOCUMENTS FILED WITH OR FURNISHED TO THE SEC,
INCLUDING THE DEFINITIVE PROXY STATEMENT AND ANY SUPPLEMENTS
THERETO AND ACCOMPANYING PROXY CARD, BECAUSE THEY CONTAIN IMPORTANT
INFORMATION. The Company’s Definitive Proxy Statement and a form of
proxy have been mailed to stockholders of the Company. No changes
have been made to the proposals to be voted on by shareholders at
the Annual Meeting Investors and stockholders can obtain a copy of
the documents filed by the Company with the SEC, including the
definitive proxy statement, free of charge by visiting the SEC’s
website, www.sec.gov and from the Company’s website
www.precipiodx.com.
About Precipio
Precipio is a healthcare biotechnology company
focused on cancer diagnostics. Our mission is to address the
pervasive problem of cancer misdiagnoses by developing solutions in
the form of diagnostic products and services. Our products and
services deliver higher accuracy, improved laboratory workflow, and
ultimately better patient outcomes, which reduce healthcare
expenses. Precipio develops innovative technologies in our
laboratory where we design, test, validate, and use these products
clinically, improving diagnostic outcomes. Precipio then
commercializes these technologies as proprietary products that
serve the global laboratory community and further scales Precipio’s
reach to eradicate misdiagnosis. For more information, please visit
www.precipiodx.com.
Please follow us on LinkedIn, Twitter
@PrecipioDx and on Facebook.
Forward-Looking Statements
This press release contains “forward-looking
statements” within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended, including, among others, including other
financial projections and potential market opportunity, plans and
prospects. Except for historical information, statements about
future volumes, sales, growth, costs, cost savings, margins,
earnings, earnings per share, diluted earnings per share, cash
flows, plans, objectives, expectations, growth or profitability are
forward-looking statements based on management’s estimates,
beliefs, assumptions and projections. Words such as “could,” “may,”
“expects,” “anticipates,” “will,” “targets,” “goals,” “projects,”
“intends,” “plans,” “believes,” “seeks,” “estimates,” “predicts,”
and variations on such words, and similar expressions that reflect
our current views with respect to future events and operational,
economic and financial performance, are intended to identify such
forward-looking statements. These forward-looking statements are
only predictions, subject to risks and uncertainties, and actual
results could differ materially from those discussed. We caution
investors not to place undue reliance on the forward-looking
statements contained in this press release. You are encouraged to
read our filings with the SEC, available at www.sec.gov, for a
discussion of these and other risks and uncertainties Important
factors that could affect performance and cause results to differ
materially from management’s expectations, or could affect the
company’s ability to achieve its strategic goals, includes factors
that are described in the sections entitled “Risk Factors” and
“Management’s Discussion and Analysis” in the company’s Annual
Report on Form 10-K for the fiscal year ended December 31, 2023, as
updated from time to time in the company’s Securities and Exchange
Commission filings. The company’s forward-looking statements in
this press release are based on management’s current views,
beliefs, assumptions and expectations regarding future events and
speak only as of the date of this release. The company undertakes
no obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise, except as required by the federal securities
laws.
Inquiries:
investors@precipiodx.com
+1-203-787-7888 Ext. 523
Precipio (NASDAQ:PRPO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Precipio (NASDAQ:PRPO)
Historical Stock Chart
From Sep 2023 to Sep 2024